144 related articles for article (PubMed ID: 31934053)
1. Rearrangement of PDGFRβ gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report.
Zheng J; Huang J; Xiao Y; Wu X; Wang K; Feng C; Gao K
Int J Clin Exp Pathol; 2019; 12(6):2284-2287. PubMed ID: 31934053
[TBL] [Abstract][Full Text] [Related]
2. [The study of 4 cases of myeloid neoplasm with t (5;12) (q33;p13) and the literatures review].
Kou L; Pan J; Qiu H; Chen S; Cen J; Zhang J; Bai S; Wu C; Wu Y; Gong Y; Shen J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):302-7. PubMed ID: 27093993
[TBL] [Abstract][Full Text] [Related]
3. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
4. Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
Cluzeau T; Lippert E; Cayuela JM; Maarek O; Migeon M; Noguera ME; Dombret H; Rea D
Eur J Haematol; 2015 Nov; 95(5):480-3. PubMed ID: 25941032
[TBL] [Abstract][Full Text] [Related]
5. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
Kulkarni S; Heath C; Parker S; Chase A; Iqbal S; Pocock CF; Kaeda J; Cwynarski K; Goldman JM; Cross NC
Cancer Res; 2000 Jul; 60(13):3592-8. PubMed ID: 10910073
[TBL] [Abstract][Full Text] [Related]
6. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
[TBL] [Abstract][Full Text] [Related]
7. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Wittman B; Horan J; Baxter J; Goldberg J; Felgar R; Baylor E; Cromwell B; Cross N; Bennett JM
Leuk Res; 2004 May; 28 Suppl 1():S65-9. PubMed ID: 15036944
[TBL] [Abstract][Full Text] [Related]
8. Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature.
Gong SL; Guo MQ; Tang GS; Zhang CL; Qiu HY; Hu XX; Yang JM
Oncol Lett; 2016 Jan; 11(1):770-774. PubMed ID: 26870282
[TBL] [Abstract][Full Text] [Related]
9. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
10. A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia.
Al-Achkar W; Wafa A; Moassass F; Othman MA
Mol Cytogenet; 2012 Aug; 5(1):36. PubMed ID: 22901309
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
12. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
15. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.
Kelly JC; Shahbazi N; Scheerle J; Jahn J; Suchen S; Christacos NC; Mowrey PN; Witt MH; Hostetter A; Meloni-Ehrig AM
Cancer Genet Cytogenet; 2009 Jul; 192(1):36-9. PubMed ID: 19480935
[TBL] [Abstract][Full Text] [Related]
16. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
17. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
[TBL] [Abstract][Full Text] [Related]
20. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
